Abstract A088: NST-628 is a potent, best-in-class MAPK pathway molecular glue that inhibits RAS- and RAF-driven cancers
Meagan B. Ryan(Sage Therapeutics (United States)), Margit Hagel(Blueprint Medicines (United States)), Klaus P. Hoeflich(Pivot), Arvin C. Dar(Memorial Sloan Kettering Cancer Center), Natasha Schenk(Novartis (United States)), Michael Hale(Sage Therapeutics (United States)), Brooke M. Swalm(Sage Therapeutics (United States)), Matthew J. Koehler, Marshall Zingg(Sage Therapeutics (United States)), Bradley J. Quade(Massachusetts General Hospital), Yongxin Han(Merck & Co., Inc., Rahway, NJ, USA (United States)), Chaoyang Ye(Blueprint Medicines (United States))
Cited by 0
Related Papers
Sequencing Chromosomal Abnormalities Reveals Neurodevelopmental Loci that Confer Risk across Diagnostic Boundaries
|Cell|2012|598
MR Imaging–guided Focused Ultrasound Surgery of Uterine Leiomyomas: A Feasibility Study
|Radiology|2003|589
Disruption of Neurexin 1 Associated with Autism Spectrum Disorder
|The American Journal of Human Genetics|2008|581
The Evolution of Protein Kinase Inhibitors from Antagonists to Agonists of Cellular Signaling
|Annual Review of Biochemistry|2011|389